SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-094124
Filing Date
2024-08-08
Accepted
2024-08-08 16:44:41
Documents
56
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tpst-20240630.htm   iXBRL 10-Q 1773364
2 EX-31.1 tpst-ex31_1.htm EX-31.1 17882
3 EX-31.2 tpst-ex31_2.htm EX-31.2 17845
4 EX-32.1 tpst-ex32_1.htm EX-32.1 8535
  Complete submission text file 0000950170-24-094124.txt   6089518

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tpst-20240630.xsd EX-101.SCH 864030
59 EXTRACTED XBRL INSTANCE DOCUMENT tpst-20240630_htm.xml XML 783517
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35890 | Film No.: 241189200
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)